Advances in Immuno-Oncology Therapeutics for Metastatic Triple-Negative Breast Cancer

Engage with this series of 4 focused ClinicalThought commentaries to gain expert insight on how to optimally integrate immunotherapy into the care of your patients with metastatic TNBC.

Share

Program Content

Activities

IO in TNBC: irAE Management
How I Manage Toxicities Associated with Immune Checkpoint Inhibition in My Patients with Metastatic TNBC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2020

Expires: March 15, 2021

IO for Metastatic TNBC
How I Am Using Immunotherapy in the Management of Metastatic TNBC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 02, 2020

Expires: April 01, 2021

IO for Early-Stage TNBC
Moving Immunotherapy Into Earlier Settings for Triple-Negative Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 17, 2020

Expires: April 16, 2021

Combination IO for mTNBC
Future Directions in Combination Immunotherapy Strategies for Metastatic Triple-Negative Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 27, 2020

Expires: April 26, 2021

Faculty

cover img faculity

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

cover img faculity

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

cover img faculity

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

cover img faculity

Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Barts Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Barts Hospital
London, United Kingdom

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only